Princess Margaret Hospital (Ontario)
Welcome,         Profile    Billing    Logout  
 14 Trials 
26 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Chen, Christine I
NCT06251076: Plan Development for Giving Teclistamab in the Outpatient Setting

Not yet recruiting
4
15
NA
Teclistamab, TECVAYLI, Tocilizumab, ACTEMRA
University Health Network, Toronto, Janssen Inc.
Multiple Myeloma, Relapsed Cancer, Refractory Cancer
04/25
09/25
BRUIN CLL-321, NCT04666038: Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
238
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Idelalisib, Zydelig, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
08/23
05/27
STOMP, NCT02343042: Selinexor and Backbone Treatments of Multiple Myeloma Patients

Hourglass Feb 2024 - Dec 2024 : Results from STOMP trial for RRMM and NDMM
Checkmark From STOMP trial in combination with Pomalyst & low dose dexamethasone for r/r multiple myeloma
Jun 2021 - Jun 2021: From STOMP trial in combination with Pomalyst & low dose dexamethasone for r/r multiple myeloma
Checkmark Data from STOMP trial in combination with lenalidomide and dexamethasone for multiple myeloma at ASH 2020
Dec 2020 - Dec 2020: Data from STOMP trial in combination with lenalidomide and dexamethasone for multiple myeloma at ASH 2020
More
Recruiting
1/2
300
Canada, US
Selinexor, KPT-330, XPOVIO®, Dexamethasone, Decadron®, Lenalidomide, Revlimid®, Pomalidomide, Pomalyst®, Bortezomib, Velcade®, Daratumumab, Darzalex®, Carfilzomib, Kyprolis®, Ixazomib, Ninlaro®, Elotuzumab, Empliciti®, Clarithromycin, Biaxin, Belantamab Mafodotin, BLENREP, Mezigdomide, BMS-986348, CC-92480
Karyopharm Therapeutics Inc, Bristol-Myers Squibb
Multiple Myeloma
04/27
04/27
Pro-M, NCT05756478: Appropriate Prescribing for Older Adults With Multimorbidity

Completed
N/A
36
RoW
Medication review
Geriatric Education and Research Institute, Tan Tock Seng Hospital, Changi General Hospital
Potentially Inappropriate Medications, Multimorbidity, Polypharmacy
10/23
10/23
ARCH-001, NCT03878407: Identification of Patients With Age-Related Clonal Hematopoiesis (ARCH) Among Cancer Survivors

Active, not recruiting
N/A
2400
Canada
Monitoring of ARCH variants
University Health Network, Toronto
Cancer
12/29
12/29
Krzyzanowska, Monika
LIBRETTO-531, NCT04211337 / 2019-001978-28: A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer

Active, not recruiting
3
291
Europe, Canada, Japan, US, RoW
Selpercatinib, LY3527723, LOXO-292, Cabozantinib, Vandetanib
Loxo Oncology, Inc., Eli Lilly and Company
Medullary Thyroid Cancer
05/23
02/26
TOPCOP3, NCT05582772: TOward a comPrehensive Supportive Care Intervention for Older Men With Metastatic Prostate Cancer

Recruiting
N/A
168
Canada
GA+M Intervention, Geriatric assessment and management, RSM intervention, Remote symptom monitoring, GA+RSM intervention, Geriatric assessment and remote symptom monitoring
University Health Network, Toronto
Metastatic Prostate Cancer
02/27
02/27
CHALLENGE, NCT00819208: Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer

Active, not recruiting
N/A
889
Europe, Canada, US, RoW
exercise intervention, counseling intervention, educational intervention, laboratory biomarker analysis, questionnaire administration, study of socioeconomic and demographic variables, fatigue assessment and management, quality-of-life assessment, Educational Intervention, Fitness testing
Canadian Cancer Trials Group, Survivorship Research Group, Queen's University, Belfast
Anxiety Disorder, Cognitive/Functional Effects, Colorectal Cancer, Depression, Fatigue, Psychosocial Effects of Cancer and Its Treatment, Sleep Disorders, Excercise
12/29
12/30
Bradbury, Penelope A
LIBRETTO-432, NCT04819100 / 2020-005191-35: A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

Active, not recruiting
3
152
Europe, Canada, Japan, US, RoW
Selpercatinib, LY3527723, LOXO-292, Placebo
Eli Lilly and Company, Loxo Oncology, Inc.
Carcinoma, Non-Small-Cell Lung
05/26
05/28
CCTG IND.238A, NCT03847649: A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies

Recruiting
2
60
Canada
Durvalumab, Prednisone, Tremelimumab
Canadian Cancer Trials Group, AstraZeneca
Cancer
04/30
04/31
NCT05714891: Neoadjuvant Platform Trial in Non-Small Cell Lung Cancer

Active, not recruiting
2
4
Canada
JDQ443
Canadian Cancer Trials Group, Novartis
NSCLC
08/26
03/28
NCT02503722: Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung Cancer

Active, not recruiting
1
36
Canada, US
Laboratory Biomarker Analysis, Osimertinib, AZD 9291, AZD-9291, AZD9291, Mereletinib, Pharmacological Study, Sapanisertib, INK-128, INK128, MLN-0128, MLN0128, TAK-228
National Cancer Institute (NCI)
Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
06/26
06/26
Sridhar, Srikala
TRANCE, NCT03432949: Radium-223 Combined With Dexamethasone as First-line Therapy in Patients With M+CRPC

Active, not recruiting
4
24
Canada
Dexamethasone plus Radium-223, Dexamethasone, Baycadron
University Health Network, Toronto, Bayer
Metastatic Prostate Cancer
09/23
07/24
MAIN-CAV, NCT05092958: Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, Study

Active, not recruiting
3
654
Canada, US
Avelumab, Bavencio, MSB 0010718C, MSB-0010718C, MSB0010718C, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Cabozantinib S-malate, BMS-907351, Cabometyx, Cometriq, XL 184, XL-184, XL184, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
National Cancer Institute (NCI)
Advanced Bladder Urothelial Carcinoma, Advanced Renal Pelvis Urothelial Carcinoma, Advanced Ureter Urothelial Carcinoma, Advanced Urethral Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8, Stage III Renal Pelvis and Ureter Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage III Urethral Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Renal Pelvis and Ureter Cancer AJCC v8, Stage IV Renal Pelvis Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8
12/25
12/25
KEYNOTE-D74, NCT05911295: Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

Recruiting
3
400
Europe, Canada, Japan, US, RoW
disitamab vedotin, RC48, RC48-ADC, pembrolizumab, KEYTRUDA®, gemcitabine, Gemzar, cisplatin, carboplatin
Seagen, a wholly owned subsidiary of Pfizer, RemeGen Co., Ltd., Merck Sharp & Dohme LLC
Urothelial Carcinoma
06/26
04/29
NCT03391479: A Study of Avelumab in Penile Cancer Who Are Unfit for or Have Progressed After Platinum-Based Chemotherapy

Recruiting
2
24
Canada
Avelumab, Best Supportive Care
University Health Network, Toronto
Penile Cancer, Advanced Cancer, Metastatic Cancer
12/24
12/24
FORAGER-1, NCT05614739: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3

Recruiting
1
535
Europe, Canada, Japan, US, RoW
LOXO-435, LY3866288, Pembrolizumab, enfortumab vedotin
Eli Lilly and Company, Merck Sharp & Dohme LLC
Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms
06/27
06/27
NCT06129084: A Study to Compare the Results of FGFR Testing by Either CtDNA Blood Testing or Standard Tumor Tissue Testing

Recruiting
N/A
260
Canada
FGFR Testing
Bernie Eigl, Vancouver Prostate Centre, Lady Davis Institute, Bladder Cancer Canada
Metastatic Bladder Cancer, Metastatic Urothelial Carcinoma
03/25
05/25
PET MUSE, NCT02462239: Impact of Positron Emission Tomography (PET) Imaging in Muscle-invasive Urothelial Carcinoma of the Bladder Staging

Completed
N/A
292
Canada
Whole-body FDG PET-CT, PET-CT imaging
Ontario Clinical Oncology Group (OCOG), Cancer Care Ontario
Muscle-invasive Bladder Cancer
03/24
11/24
TOPCOP3, NCT05582772: TOward a comPrehensive Supportive Care Intervention for Older Men With Metastatic Prostate Cancer

Recruiting
N/A
168
Canada
GA+M Intervention, Geriatric assessment and management, RSM intervention, Remote symptom monitoring, GA+RSM intervention, Geriatric assessment and remote symptom monitoring
University Health Network, Toronto
Metastatic Prostate Cancer
02/27
02/27
Tsang, Erica
ABLATE, NCT06453486: A Study of High Dose Radiation Therapy for Locally Advanced Pancreatic Cancer That Responded to Initial Chemotherapy Treatment

Recruiting
2
43
Canada
High dose radiation therapy
University Health Network, Toronto
Locally Advanced Pancreatic Adenocarcinoma
04/30
04/30
NCT05411094: Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer

Recruiting
1
18
Canada, US
Biopsy Procedure, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI 4736, MEDI-4736, MEDI4736, Olaparib, AZD 2281, AZD-2281, AZD2281, KU 0059436, KU-0059436, KU0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Radiologic Examination, Radiologic Evaluation, Radiologic Exam
National Cancer Institute (NCI)
Locally Advanced Pancreatic Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Unresectable Pancreatic Carcinoma
09/25
05/27
MOONRAY-01, NCT06586515: , A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

Recruiting
1
570
Europe, Canada, Japan, US, RoW
LY3962673, Cetuximab, Gemcitabine, nab-paclitaxel, Oxaliplatin, leucovorin, Irinotecan, 5-fluorouracil
Eli Lilly and Company, Loxo Oncology, Inc.
Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer
03/29
03/29
TORL4500-001, NCT06005740: A Phase 1, First in Human Study of TORL-4-500 in Patients with Advanced Cancer

Recruiting
1
70
Canada, US
TORL-4-500
TORL Biotherapeutics, LLC, Translational Research in Oncology
Advanced Solid Tumor, Hepatocellular Carcinoma
10/25
10/26
PEGASUS, NCT05132244: Monitoring and Managing Glucose Levels in People With Pancreatic Cancer

Recruiting
N/A
50
Canada
Endocrinologist-directed target blood glucose level 4-10 mmol/L using data from a continuous glucose monitor (CGM), Standard Care
British Columbia Cancer Agency, University of British Columbia
Pancreatic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, Hyperglycemia
04/26
04/27
ProsperPanc, NCT05927298: Province of Ontario Strategy for Personalized Management of Pancreatic Cancer Trial

Recruiting
N/A
200
Canada
Non-interventional
University Health Network, Toronto, Ontario Institute for Cancer Research, Ottawa Hospital Research Institute, Lawson Health Research Institute
Pancreas Cancer
03/27
03/27
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Chen, Christine I
NCT06251076: Plan Development for Giving Teclistamab in the Outpatient Setting

Not yet recruiting
4
15
NA
Teclistamab, TECVAYLI, Tocilizumab, ACTEMRA
University Health Network, Toronto, Janssen Inc.
Multiple Myeloma, Relapsed Cancer, Refractory Cancer
04/25
09/25
BRUIN CLL-321, NCT04666038: Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
238
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Idelalisib, Zydelig, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
08/23
05/27
STOMP, NCT02343042: Selinexor and Backbone Treatments of Multiple Myeloma Patients

Hourglass Feb 2024 - Dec 2024 : Results from STOMP trial for RRMM and NDMM
Checkmark From STOMP trial in combination with Pomalyst & low dose dexamethasone for r/r multiple myeloma
Jun 2021 - Jun 2021: From STOMP trial in combination with Pomalyst & low dose dexamethasone for r/r multiple myeloma
Checkmark Data from STOMP trial in combination with lenalidomide and dexamethasone for multiple myeloma at ASH 2020
Dec 2020 - Dec 2020: Data from STOMP trial in combination with lenalidomide and dexamethasone for multiple myeloma at ASH 2020
More
Recruiting
1/2
300
Canada, US
Selinexor, KPT-330, XPOVIO®, Dexamethasone, Decadron®, Lenalidomide, Revlimid®, Pomalidomide, Pomalyst®, Bortezomib, Velcade®, Daratumumab, Darzalex®, Carfilzomib, Kyprolis®, Ixazomib, Ninlaro®, Elotuzumab, Empliciti®, Clarithromycin, Biaxin, Belantamab Mafodotin, BLENREP, Mezigdomide, BMS-986348, CC-92480
Karyopharm Therapeutics Inc, Bristol-Myers Squibb
Multiple Myeloma
04/27
04/27
Pro-M, NCT05756478: Appropriate Prescribing for Older Adults With Multimorbidity

Completed
N/A
36
RoW
Medication review
Geriatric Education and Research Institute, Tan Tock Seng Hospital, Changi General Hospital
Potentially Inappropriate Medications, Multimorbidity, Polypharmacy
10/23
10/23
ARCH-001, NCT03878407: Identification of Patients With Age-Related Clonal Hematopoiesis (ARCH) Among Cancer Survivors

Active, not recruiting
N/A
2400
Canada
Monitoring of ARCH variants
University Health Network, Toronto
Cancer
12/29
12/29
Krzyzanowska, Monika
LIBRETTO-531, NCT04211337 / 2019-001978-28: A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer

Active, not recruiting
3
291
Europe, Canada, Japan, US, RoW
Selpercatinib, LY3527723, LOXO-292, Cabozantinib, Vandetanib
Loxo Oncology, Inc., Eli Lilly and Company
Medullary Thyroid Cancer
05/23
02/26
TOPCOP3, NCT05582772: TOward a comPrehensive Supportive Care Intervention for Older Men With Metastatic Prostate Cancer

Recruiting
N/A
168
Canada
GA+M Intervention, Geriatric assessment and management, RSM intervention, Remote symptom monitoring, GA+RSM intervention, Geriatric assessment and remote symptom monitoring
University Health Network, Toronto
Metastatic Prostate Cancer
02/27
02/27
CHALLENGE, NCT00819208: Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer

Active, not recruiting
N/A
889
Europe, Canada, US, RoW
exercise intervention, counseling intervention, educational intervention, laboratory biomarker analysis, questionnaire administration, study of socioeconomic and demographic variables, fatigue assessment and management, quality-of-life assessment, Educational Intervention, Fitness testing
Canadian Cancer Trials Group, Survivorship Research Group, Queen's University, Belfast
Anxiety Disorder, Cognitive/Functional Effects, Colorectal Cancer, Depression, Fatigue, Psychosocial Effects of Cancer and Its Treatment, Sleep Disorders, Excercise
12/29
12/30
Bradbury, Penelope A
LIBRETTO-432, NCT04819100 / 2020-005191-35: A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

Active, not recruiting
3
152
Europe, Canada, Japan, US, RoW
Selpercatinib, LY3527723, LOXO-292, Placebo
Eli Lilly and Company, Loxo Oncology, Inc.
Carcinoma, Non-Small-Cell Lung
05/26
05/28
CCTG IND.238A, NCT03847649: A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies

Recruiting
2
60
Canada
Durvalumab, Prednisone, Tremelimumab
Canadian Cancer Trials Group, AstraZeneca
Cancer
04/30
04/31
NCT05714891: Neoadjuvant Platform Trial in Non-Small Cell Lung Cancer

Active, not recruiting
2
4
Canada
JDQ443
Canadian Cancer Trials Group, Novartis
NSCLC
08/26
03/28
NCT02503722: Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung Cancer

Active, not recruiting
1
36
Canada, US
Laboratory Biomarker Analysis, Osimertinib, AZD 9291, AZD-9291, AZD9291, Mereletinib, Pharmacological Study, Sapanisertib, INK-128, INK128, MLN-0128, MLN0128, TAK-228
National Cancer Institute (NCI)
Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
06/26
06/26
Sridhar, Srikala
TRANCE, NCT03432949: Radium-223 Combined With Dexamethasone as First-line Therapy in Patients With M+CRPC

Active, not recruiting
4
24
Canada
Dexamethasone plus Radium-223, Dexamethasone, Baycadron
University Health Network, Toronto, Bayer
Metastatic Prostate Cancer
09/23
07/24
MAIN-CAV, NCT05092958: Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, Study

Active, not recruiting
3
654
Canada, US
Avelumab, Bavencio, MSB 0010718C, MSB-0010718C, MSB0010718C, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Cabozantinib S-malate, BMS-907351, Cabometyx, Cometriq, XL 184, XL-184, XL184, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
National Cancer Institute (NCI)
Advanced Bladder Urothelial Carcinoma, Advanced Renal Pelvis Urothelial Carcinoma, Advanced Ureter Urothelial Carcinoma, Advanced Urethral Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8, Stage III Renal Pelvis and Ureter Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage III Urethral Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Renal Pelvis and Ureter Cancer AJCC v8, Stage IV Renal Pelvis Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8
12/25
12/25
KEYNOTE-D74, NCT05911295: Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

Recruiting
3
400
Europe, Canada, Japan, US, RoW
disitamab vedotin, RC48, RC48-ADC, pembrolizumab, KEYTRUDA®, gemcitabine, Gemzar, cisplatin, carboplatin
Seagen, a wholly owned subsidiary of Pfizer, RemeGen Co., Ltd., Merck Sharp & Dohme LLC
Urothelial Carcinoma
06/26
04/29
NCT03391479: A Study of Avelumab in Penile Cancer Who Are Unfit for or Have Progressed After Platinum-Based Chemotherapy

Recruiting
2
24
Canada
Avelumab, Best Supportive Care
University Health Network, Toronto
Penile Cancer, Advanced Cancer, Metastatic Cancer
12/24
12/24
FORAGER-1, NCT05614739: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3

Recruiting
1
535
Europe, Canada, Japan, US, RoW
LOXO-435, LY3866288, Pembrolizumab, enfortumab vedotin
Eli Lilly and Company, Merck Sharp & Dohme LLC
Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms
06/27
06/27
NCT06129084: A Study to Compare the Results of FGFR Testing by Either CtDNA Blood Testing or Standard Tumor Tissue Testing

Recruiting
N/A
260
Canada
FGFR Testing
Bernie Eigl, Vancouver Prostate Centre, Lady Davis Institute, Bladder Cancer Canada
Metastatic Bladder Cancer, Metastatic Urothelial Carcinoma
03/25
05/25
PET MUSE, NCT02462239: Impact of Positron Emission Tomography (PET) Imaging in Muscle-invasive Urothelial Carcinoma of the Bladder Staging

Completed
N/A
292
Canada
Whole-body FDG PET-CT, PET-CT imaging
Ontario Clinical Oncology Group (OCOG), Cancer Care Ontario
Muscle-invasive Bladder Cancer
03/24
11/24
TOPCOP3, NCT05582772: TOward a comPrehensive Supportive Care Intervention for Older Men With Metastatic Prostate Cancer

Recruiting
N/A
168
Canada
GA+M Intervention, Geriatric assessment and management, RSM intervention, Remote symptom monitoring, GA+RSM intervention, Geriatric assessment and remote symptom monitoring
University Health Network, Toronto
Metastatic Prostate Cancer
02/27
02/27
Tsang, Erica
ABLATE, NCT06453486: A Study of High Dose Radiation Therapy for Locally Advanced Pancreatic Cancer That Responded to Initial Chemotherapy Treatment

Recruiting
2
43
Canada
High dose radiation therapy
University Health Network, Toronto
Locally Advanced Pancreatic Adenocarcinoma
04/30
04/30
NCT05411094: Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer

Recruiting
1
18
Canada, US
Biopsy Procedure, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI 4736, MEDI-4736, MEDI4736, Olaparib, AZD 2281, AZD-2281, AZD2281, KU 0059436, KU-0059436, KU0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Radiologic Examination, Radiologic Evaluation, Radiologic Exam
National Cancer Institute (NCI)
Locally Advanced Pancreatic Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Unresectable Pancreatic Carcinoma
09/25
05/27
MOONRAY-01, NCT06586515: , A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

Recruiting
1
570
Europe, Canada, Japan, US, RoW
LY3962673, Cetuximab, Gemcitabine, nab-paclitaxel, Oxaliplatin, leucovorin, Irinotecan, 5-fluorouracil
Eli Lilly and Company, Loxo Oncology, Inc.
Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer
03/29
03/29
TORL4500-001, NCT06005740: A Phase 1, First in Human Study of TORL-4-500 in Patients with Advanced Cancer

Recruiting
1
70
Canada, US
TORL-4-500
TORL Biotherapeutics, LLC, Translational Research in Oncology
Advanced Solid Tumor, Hepatocellular Carcinoma
10/25
10/26
PEGASUS, NCT05132244: Monitoring and Managing Glucose Levels in People With Pancreatic Cancer

Recruiting
N/A
50
Canada
Endocrinologist-directed target blood glucose level 4-10 mmol/L using data from a continuous glucose monitor (CGM), Standard Care
British Columbia Cancer Agency, University of British Columbia
Pancreatic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, Hyperglycemia
04/26
04/27
ProsperPanc, NCT05927298: Province of Ontario Strategy for Personalized Management of Pancreatic Cancer Trial

Recruiting
N/A
200
Canada
Non-interventional
University Health Network, Toronto, Ontario Institute for Cancer Research, Ottawa Hospital Research Institute, Lawson Health Research Institute
Pancreas Cancer
03/27
03/27

Download Options